Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty-a BOLD analysis by Burney, P et al.
ORIGINAL ARTICLE
Chronic obstructive pulmonary disease mortality
and prevalence: the associations with smoking
and poverty—a BOLD analysis
Peter Burney,1 Anamika Jithoo,1 Bernet Kato,1 Christer Janson,2 David Mannino,3
Ewa Niżankowska-Mogilnicka,4 Michael Studnicka,5 Wan Tan,6 Eric Bateman,7
Ali Koçabas,8 William M Vollmer,9 Thorarrin Gislason,10 Guy Marks,11
Parvaiz A Koul,12 Imed Harrabi,13 Louisa Gnatiuc,1 Sonia Buist,14 for the Burden
of Obstructive Lung Disease (BOLD) Study
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
thoraxjnl-2013-204460).
For numbered afﬁliations see
end of article.
Correspondence to
Professor Peter Burney,
National Heart & Lung
Institute, Imperial College,
1 Manresa Road, London
SW3 6LR, UK;
p.burney@imperial.ac.uk
Received 2 September 2013
Revised 20 November 2013
Accepted 22 November 2013
Published Online First
18 December 2013
To cite: Burney P, Jithoo A,
Kato B, et al. Thorax
2014;69:465–473.
ABSTRACT
Background Chronic obstructive pulmonary disease
(COPD) is a commonly reported cause of death and
associated with smoking. However, COPD mortality is
high in poor countries with low smoking rates.
Spirometric restriction predicts mortality better than
airﬂow obstruction, suggesting that the prevalence of
restriction could explain mortality rates attributed to
COPD. We have studied associations between mortality
from COPD and low lung function, and between both
lung function and death rates and cigarette consumption
and gross national income per capita (GNI).
Methods National COPD mortality rates were regressed
against the prevalence of airﬂow obstruction and
spirometric restriction in 22 Burden of Obstructive Lung
Disease (BOLD) study sites and against GNI, and
national smoking prevalence. The prevalence of airﬂow
obstruction and spirometric restriction in the BOLD sites
were regressed against GNI and mean pack years
smoked.
Results National COPD mortality rates were more
strongly associated with spirometric restriction in the
BOLD sites (<60 years: men rs=0.73, p=0.0001; women
rs=0.90, p<0.0001; 60+ years: men rs=0.63,
p=0.0022; women rs=0.37, p=0.1) than obstruction
(<60 years: men rs=0.28, p=0.20; women rs=0.17,
p<0.46; 60+ years: men rs=0.28, p=0.23; women
rs=0.22, p=0.33). Obstruction increased with mean pack
years smoked, but COPD mortality fell with increased
cigarette consumption and rose rapidly as GNI fell below
US$15 000. Prevalence of restriction was not associated
with smoking but also increased rapidly as GNI fell
below US$15 000.
Conclusions Smoking remains the single most
important cause of obstruction but a high prevalence of
restriction associated with poverty could explain the high
‘COPD’ mortality in poor countries.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
now the third most common cause of death in the
world.1 COPD is deﬁned in terms of airﬂow
obstruction and operationalised as a low ratio of
forced expiratory volume in 1 s (FEV1) to forced
vital capacity (FVC).2 By far the strongest risk
factors for airﬂow obstruction are smoking and
exposure to environmental tobacco smoke,3but
many areas of the world with high mortality rates
from ‘COPD’ still have low consumption of
tobacco.4 The distribution of death from COPD in
the UK is not the same as that of lung cancer, the
disease most strongly associated with tobacco con-
sumption, but is more closely associated with low
social status5 and poverty.6
A low FEV1 is associated with increased mortal-
ity, including a high mortality from cardiovascular
disease,7 but there is also evidence of an association
with a low FVC, a measure correlated with the
FEV1.
8 9 When these two measures are analysed
together, the high mortality is associated with the
spirometric restriction and not with airﬂow
obstruction.10
We examined the relation of national mortality
rates from COPD, as recorded by the global health
observatory, with the prevalence of airﬂow obstruc-
tion and spirometric restriction in 22 Burden of
Obstructive Lung Disease (BOLD) study sites, and
with the prevalence of smoking and poverty. We
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Key messages
What is the key question?
▸ What is the relation between the global
distribution of chronic obstructive pulmonary
disease (COPD) mortality, the prevalence of
abnormal lung function, smoking and poverty?
What is the bottom line?
▸ Smoking prevalence correlates with airﬂow
obstruction, but not with mortality from COPD;
COPD mortality is associated with low vital
capacity; COPD mortality and low vital capacity
are associated with poverty.
Why read on?
▸ Between 1990 and 2010, COPD rose from the
fourth to the third most common cause of
death globally. Adequate understanding of the
distribution of COPD mortality is the key to
ﬁnding an adequate response.
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also used the BOLD data from 22 sites to describe the distribu-
tion of airﬂow obstruction (FEV1/FVC less than the lower limit
of normal (<LLN)) and spirometric restriction (FVC<LLN)
across these sites and their relation with smoking prevalence
and poverty stratiﬁed by sex.
METHODS
The design and rationale for the BOLD study, the characteristics
of samples and the prevalence of COPD in 14 sites have been
reported elsewhere.3 11–13 Data collection from an additional
eight sites has been completed since these earlier publications
and added to the dataset for these analyses. The study popula-
tion comprised non-institutionalised people aged 40 years and
older stratiﬁed by sex.
BOLD sites are selected to represent the Global Burden of
Disease regions, giving greater weight to larger regions but still
ensuring at least two sites in most regions. Within regions, selec-
tion of sites is largely dependent on the availability of suitable
collaborators, but sites are asked to sample from substantial
populations of over 250 000 from predeﬁned administrative
areas to avoid highly exceptional populations.
Response rates were deﬁned as the number of responders
(those who completed the core questionnaire and post-
bronchodilator spirometry) divided by the total number of indi-
viduals contacted. Cooperation rates were deﬁned as the
number of responders divided by the total number of respon-
ders plus active refusers.
Lung function, including FEV1 and FVC, was measured using
the ndd EasyOne Spirometer (ndd Medizintechnik AG, Zurich,
Switzerland), before and 15 min after inhaling salbutamol
(200 μg) from a metered dose inhaler through a spacer.
Spirograms were reviewed by the BOLD Pulmonary Function
Reading Centre, and assigned a quality score based on accept-
ability and reproducibility criteria from the American Thoracic
Society (ATS) and European Respiratory Society (ERS).14
Spirometry technicians at BOLD sites were certiﬁed before data
collection, received regular feedback on quality and were
required to maintain a prespeciﬁed quality standard.
Outcome measures were airﬂow obstruction, deﬁned as a
post-bronchodilator FEV1/FVC ratio below the LLN for age and
sex,15 based on reference equations for Caucasians derived from
the third US National Health and Nutrition Examination
Survey,16 and spirometric restriction deﬁned as a post-
bronchodilator FVC below the LLN for height, age and sex,
based on the same reference population.
Information on respiratory symptoms, health status and expos-
ure to risk factors was obtained from face-to-face interviews con-
ducted in the subject’s native language by trained and certiﬁed
staff. Questions were derived from the 1978 ATS Epidemiology
Standardisation Project,17 the European Community Respiratory
Health Survey,18 the Consilio Nazionale Ricerche study,19 and
the Obstructive Lung Disease in North Sweden study.20
National mortality data for 193 countries were obtained from
the World Health Organization21 for two age groups, 15–59
and 60+ years, and expressed as rates/100 000 population. For
each site we estimated for the age groups 40–59 years and 60
+ years the prevalence of airﬂow obstruction and the prevalence
of spirometric restriction using sampling weights to account for
the sampling strategies in each site.
We compared the national COPD mortality rates against the
prevalence of airﬂow obstruction and of spirometric restriction
in the BOLD centres using Spearman rank correlation. We then
regressed the same mortality rates against the gross national
income (GNI) per person for the country using data from the
World Bank and expressed as US dollars ($US) adjusted for pur-
chasing power parity (PPP)22 and the age-standardised national
prevalence of cigarette smoking obtained from the Tobacco
Atlas.23
We ﬁnally regressed the prevalence of airﬂow obstruction and
spirometric restriction against the mean pack years smoked in
the site and against the GNI22 and plotted the results.
We do not expect the variance of the regression errors to be
equal across observations (homoscedasticity) because the
outcome and predictor variables in the regression models reﬂect
‘means’ of variables (rather than individual observations) from
populations that vary in size. Therefore we used weighted least
squares regression for which the weight is the population.24 The
bigger the population the smaller the variance of the regression
errors. In the models for national mortality data, the weight is
the total number of men and women in the relevant age group
in each country. In the regression models for prevalence of
airﬂow obstruction and spirometric restriction, the weight is the
total number of people with acceptable spirometry data in each
site. For each model ﬁtted residuals were plotted against the pre-
dicted values to investigate linearity of associations. When asso-
ciations were not linear we transformed the predictor variable.
When looking at the relationships between national mortality
levels from COPD and GNI we used log GNI as the predictor
variable whereas when looking at the relationship between
spirometric restriction and GNI, we used 1/GNI.
To test the robustness of our ﬁndings to missing data, we
reran the analyses involving data from the BOLD sites after
excluding those sites that had a cooperation rate of less
than 60%.
All analyses were done using Stata V.12 (Stata Corporation,
College Station, Texas, USA). The correlation coefﬁcients
quoted are Spearman’s rank correlation coefﬁcients (rs). If
appropriate, robust SEs were computed to take account of any
clustering within countries. Ethical approval was obtained by
each site from the local ethical committee and written informed
consent was obtained from every participant.
RESULTS
The sampling design used at each BOLD site is presented in
online supplementary table E1 together with information on
response and cooperation rates at each site. A third of the sites
had cooperation rates above 80%, a third between 60% and
79% and a third below 60%. Low and middle income countries
and Nordic countries had the highest cooperation rates.
The estimated prevalence of airﬂow obstruction aged 40 years
and over ranged among men from 5.7% (Pune, India) to 23.0%
(Cape Town, South Africa), and among women from 4.2%
(Nampicuan, The Philippines) to 20.7% (Uppsala, Sweden)
(table 1). The prevalence of spirometric restriction was much
more variable, ranging among men from 8.4% (Bergen,
Norway) to 67.7% (Mumbai, India) and among women from
6.7% (Bergen, Norway) to 70.5% (Srinegar, India).
The national mortality rates attributed to COPD in those aged
15–59 years were strongly correlated with the local prevalence of
spirometric restriction in the BOLD sites in those aged 40–59
(men: rs=+0.73, p=0.0001; women rs=+0.90, p≤0.0001) but
not with the prevalence of airway obstruction (men: rs=+0.28,
p=0.2; women: rs=+0.17, p=0.46). Similarly the national mor-
tality rates attributed to COPD in those aged 60+ years were
strongly correlated with the local prevalence of spirometric
restriction in the BOLD sites in those over 60 years old (men:
rs=+0.63, p=0.0022; women: rs=+0.37, p=0.1) but not with
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Table 1 Number of participants included, prevalence of airflow obstruction (FEV1/FVC<LLN) and low FVC (<LLN) and mean pack years smoked from the BOLD sites for men and women separately,
and GNI/capita ($US PPP) and national smoking rates for men and women for countries containing BOLD sites
Site (dates of fieldwork) N
Prevalence of airflow
obstruction (% FEV1/
FVC<LLN): men
Prevalence of low
FVC (% FVC<LLN):
men
Smoking (mean
pack years):
men
Prevalence of airflow
obstruction (% FEV1/
FVC<LLN): women
Prevalence of low
FVC (% FVC<LLN):
women
Smoking (mean
pack years):
women
National GNI/
capita($US
PPP)
National cigarette
consumption
(current
prevalence %)
Adult
men
Adult
women
Guangzhou, China (2003) 473 9.3 30.0 21.5 6.3 30.5 1.0 6230 59.5 3.7
Mumbai, India (2006/8) 440 6.0 67.7 2.0 7.6 68.7 0.0 3000 27.6 1
Pune, India (2008/9) 849 5.7 63.1 1.2 6.8 70.5 0.1 3000 27.6 1
Srinagar, India (2010/11) 763 17.3 25.3 24.2 14.8 31.2 1.3 3000 27.6 1
Manila, The Philippines (2005/6) 893 15.1 62.4 18.7 4.2 62.9 2.7 3680 38.9 8.5
Nampicuan-Talugtug, The
Philippines (2008/9)
722 16.9 52.7 20.6 13.5 61.0 3.3 3680 38.9 8.5
Sydney, Australia (2006/7) 541 7.6 16.1 14.1 14.1 9.4 9.9 35610 – –
Krakow, Poland (2005) 526 14.9 10.7 23.7 12.2 9.6 7.5 17690 43.9 27.2
Tartu, Estonia (2008/10) 615 7.9 11.0 12.7 4.9 6.7 2.8 20630 49.9 27.5
Bergen, Norway (2005/6) 658 13.8 8.4 14.7 10.0 9.9 10.0 60220 33.6 30.4
Hannover, Germany (2005) 683 9.9 10.8 19.7 6.8 7.7 11.1 37540 – –
Lisbon, Portugal (2008) 714 9.3 12.0 21.4 7.4 9.5 3.4 24060 40.6 31
London, UK (2006/7) 677 19.5 22.1 19.6 16.0 14.2 11.9 37490 – –
Maastricht, The Netherlands
(2007/9)
590 19.7 11.0 15.3 17.9 9.3 9.1 41840 38.3 30.3
Reykjavik, Iceland (2004/5) 757 9.2 14.9 13.9 13.5 10.0 9.8 30900 26.1 26.6
Salzburg, Austria (2004/5) 1258 13.4 11.0 17.1 20.7 8.2 8.4 39720 46.4 40.1
Uppsala, Sweden (2006/7) 547 10.5 10.2 12.2 8.7 10.0 8.0 40850 19.6 24.5
Adana, Turkey (2003/4) 806 19.8 13.1 27.0 9.1 15.7 4.3 14820 51.6 19.2
Lexington, USA (2005/6) 508 12.3 25.7 30.1 16.2 26.1 19.0 47280 – –
Vancouver, Canada (2005/6) 827 14.5 8.4 15.0 12.5 8.4 9.2 38500 19 17.5
Cape Town, South Africa (2005) 847 23.0 47.6 16.1 16.9 46.1 8.7 10090 25 7.8
Sousse, Tunisia (2010/12) 661 8.6 25.1 2.1 1.8 27.2 0.0 8390 46.5 1
BOLD, Burden of Obstructive Lung Disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GNI, gross national income; LLN, lower limit of normal; PPP, purchasing power parity.
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the prevalence of airﬂow obstruction (men: rs=+0.28; p=0.23;
women: rs=+0.22, p=0.33).
Plots of COPD mortality rates for the 179 countries with
available data showed a strong inverse association with GNI,
with rates rising rapidly as GNI fell below US$15 000 per capita
per annum (ﬁgure 1A) and showed no clear positive association
with the age standardised prevalence of cigarette smoking in the
135 countries with available data (ﬁgure 1B).
Regression of national mortality rates from COPD against the
logarithm of the GNI showed a strong negative association for
both sexes and for both age groups (15–59 years and 60
+ years) (p<0.001 in all cases) (table 2). For the 19 countries
with BOLD data this association was qualitatively similar,
though the regression coefﬁcients were stronger (table 2).
Table 2 also shows the results of regressing mortality rates
from COPD against national smoking rates. Coefﬁcients are sig-
niﬁcantly negative for both age groups and both sexes. When
this analysis was repeated using the local estimates of mean
cumulative pack years smoked by the whole population in the
22 BOLD sites there was also a signiﬁcant negative association
in all groups with more smoking being associated with a lower
national mortality rate for COPD (table 2).
Although mortality from COPD was negatively associated with
smoking, whether measured as the national age-standardised
prevalence or as the local mean cumulative pack years smoked,
there was a clear positive association between the prevalence of
airﬂow obstruction and the mean pack years smoked in the 22
BOLD sites (ﬁgure 2A) accounting for 37% of the variance in
men (p=0.003) and 35% of the variance in women (p=0.004)
(table 3). The prevalence of airﬂow obstruction increased by
4.0% per 10 pack years smoked in men and by 6.7% per 10 pack
years in women. The association between prevalence of airﬂow
obstruction and GNI was weakly positive but not signiﬁcant
(men: p=0.78; women p=0.06) (ﬁgure 2B; table 3).
Table 3 also shows that spirometric restriction was slightly
more common when smoking rates were higher, an association
that was statistically signiﬁcant for women (p=0.021) but not
for men (p=0.071) (ﬁgure 3A; table 3). There was, however, a
strong association between the prevalence of spirometric restric-
tion and a lower GNI (men p<0001; women p<0.001) with
rates rising rapidly as GNI fell below US$15 000/capita/annum
(table 3; ﬁgure 3B).
When we reran the analyses reported in tables 2 and 3 after
excluding the BOLD sites that had a cooperation rate of less
than 60% the associations that we found were qualitatively
similar to those using all the sites (see online supplementary
tables E2 and E3).
DISCUSSION
The poor correlation between mortality rates from COPD and
the prevalence of smoking has been remarked on before at the
national6 and international level,4 25 but the ﬁndings from
BOLD go further in showing that smoking is a good predictor
of the prevalence of airﬂow obstruction. Other causes of airﬂow
obstruction, such as biomass exposure, are not therefore
required to explain any discrepancy between the prevalence of
obstruction and the prevalence of smoking.4
The strong relation of COPD mortality with poverty has also
been described at a national level,6 and in England and Wales
the social class gradient for COPD mortality is steeper than for
either lung cancer or even tuberculosis.5 The implications for
global health, however, have not been widely understood. Nor
has the similarity of the global distributions of COPD mortality
and the prevalence of spirometric restriction or their relation to
the per capita GNI.
The prevalence of airﬂow obstruction correlates well with the
mean pack years smoked in the BOLD sites and with national
estimates of the prevalence of smoking. However, the national
Figure 1 Age standardised national chronic obstructive pulmonary disease (COPD) mortality (age 15+ years) by sex and (A) annual per capita
gross national income and (B) age-standardised national smoking prevalence. PPP, purchasing power parity.
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mortality rates from ‘COPD’ do not correlate with either the
national prevalence of smoking or with the local prevalence of
airﬂow obstruction. However, they do correlate well with the
prevalence of spirometric restriction. Both ‘COPD’ mortality
rates and the prevalence of spirometric restriction are strongly
associated with the GNI per head of population, each rising
steeply as GNI/capita falls below US$15 000 PPP.
Although we do not yet have direct evidence from the BOLD
study, evidence from the USA shows that the FVC is a much
stronger determinant of survival than the FEV1/FVC ratio.
10 In
population surveys it is unlikely that spirometric restriction
represents severe obstruction, as it may do in clinics in which
gas trapping due to obstruction may reduce the FVC. First, we
found no association between the prevalence of airﬂow obstruc-
tion and spirometric restriction; second, in younger adults the
FVC relates well to the total lung capacity;26 third, there is evi-
dence among older people that the total lung capacity is also a
good predictor of mortality and use of services;27 and ﬁnally,
the BOLD sites with spirometric restriction are not those with a
high prevalence of obstruction.
Table 2 Association of national mortality levels from COPD with logarithm of GNI/capita ($US PPP) for all 179 countries with information and
for the 19 countries with BOLD sites, and age-adjusted national smoking prevalence for 135 available countries and with mean pack years
smoked for 22 BOLD sites
Men Women
β 95% CI p Value β 95% CI p Value
GNI
Age 15–59 years
Log GNI (N=179) −4.64 −5.58 to −3.69 <0.001 −2.87 −3.55 to −2.20 <0.001
Log GNI (BOLD countries: N=19) −7.90 −11.24 to −4.55 <0.001 −4.91 −7.04 to −2.78 <0.001
Age >60 years
Log GNI (N=179) −196 −235 to −158 <0.001 −144 −179 to −109 <0.001
Log GNI (BOLD countries: N=19) −329 −388 to −270 <0.001 −259 −326 to −192 <0.001
Smoking
Age 15–59 years
Age-adjusted smoking prevalence (%) (N=135) −0.31 −0.41 to −0.22 <0.001 −0.51 −0.63 to −0.39 <0.001
Mean pack years (BOLD sites: N=22) −0.52 −0.98 to −0.07 0.027 −0.74 −1.34 to −0.14 0.019
Age >60 years
Age-adjusted smoking prevalence (%) (N=135) −5.57 −9.987 to −1.164 0.014 −24.47 −28.59 to −20.36 <0.001
Mean pack years (BOLD sites: N=22) −18.5 −31.4 to −5.5 0.008 −39.0 −58.0 to −19.9 <0.001
BOLD, Burden of Obstructive Lung Disease; COPD, chronic obstructive pulmonary disease; GNI, gross national income; PPP, purchasing power parity.
Figure 2 Prevalence of airﬂow obstruction (FEV1/FVC<LLN) by sex and (A) mean pack years smoked and (B) annual per capita gross national
income. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; LLN, lower limit of normal; PPP, purchasing power parity.
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‘COPD’ is deﬁned in terms of chronic airﬂow limitation2 but
this deﬁnition has its limitations28 and in surveys the association
between self-reported ‘COPD’ and airﬂow obstruction is
weak.29 Given that very few people will have had spirometry,
this discrepancy is unsurprising. In addition, given the difﬁculty
in ante-mortem diagnosis, it is understandable if those with
spirometric restriction and without airﬂow obstruction are certi-
ﬁed as having died of ‘COPD’.
The BOLD project is the largest and most ambitious attempt
to date to quantify the global variation in ventilatory function
with associated symptoms and risk factors. The quality of lung
function data from the BOLD study is controlled at a high level.
All technicians were trained according to a common protocol
and all the spirometric tracings were checked centrally for
quality during the ﬁeldwork and errors fed back to the techni-
cians. When readings were inadequate, technicians were sus-
pended until they had been retrained. Spirometry that did not
reach ATS/ERS standards was rejected. Estimates of deaths by
cause were taken from the Global Health Observatory of the
World Health Organization21 and were calculated using
methods summarised elsewhere.30
In some BOLD sites the estimates of prevalence are based on
studies with relatively low response rates, but when we omitted
all sites with a cooperation rate below 60%, the results did not
materially change. There are very few data missing from
national sources and those that are missing are generally from
small countries. The main exceptions are a small number of
large countries, such as the USA, Germany and Australia with
missing smoking data. This small number of missing units is
unlikely to make any difference to the results.
In comparing data from the BOLD sites with national data on
smoking, income or mortality we are making an assumption
that the sites are representative of their country. Formally this is
not the case, but the assumption is nevertheless not
Table 3 Association of prevalence of airflow obstruction (%FEV1/FVC<LLN), spirometric restriction (% FVC <LLN) with mean pack years
smoked and GNI/capita ($US PPP) in 22 BOLD sites
Men Women
β 95% CI p Value β 95% CI p Value
Airflow obstruction
Mean pack years 0.40 0.15 to 0.64 0.003 0.67 0.24 to 1.10 0.004
GNI (per US$1000 PPP) 0.02 −0.10 to 0.13 0.78 0.12 −0.01 to 0.25 0.063
Spirometric restriction
Mean pack years −1.07 −2.24 to 0.10 0.071 −2.32 −4.25 to −0.40 0.021
1/GNI (per US$1000 PPP) 140 101 to 179 <0.001 168 115 to 221 <0.001
BOLD, Burden of Obstructive Lung Disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GNI, gross national income; LLN, lower limit of normal; PPP, purchasing
power parity.
Figure 3 Prevalence of a spirometric restriction (FVC<LLN) by (A) mean pack years smoked and (B) annual per capita gross national income. FVC,
forced vital capacity; LLN, lower limit of normal; PPP, purchasing power parity.
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unreasonable. First, although the sites were not randomly
selected from all possible sites, we took care to sample from
well deﬁned and relatively large populations to avoid very
special groups. Second, when we compare the BOLD data and
the national data for smoking prevalence, we get very similar
results. Third we know that the within-country variation in mor-
tality is much less than the between-country variation, even in
relatively homogeneous regions such as Europe.31 Finally,
although in principle a misclassiﬁcation arising from this
assumption could explain a lack of association, it is unlikely to
explain a strong association such as that between the prevalence
of spirometric restriction and GNI.
The lack of association between smoking prevalence and mor-
tality from ‘COPD’ is explained by the inverse association
between poverty and smoking prevalence. At an individual level
there is strong evidence from the BOLD study for an association
between airﬂow obstruction and smoking,12 an association also
reﬂected in the BOLD study at an ecological level (ﬁgure 2A).
At an ecological level, however, there is no association between
smoking and mortality from ‘COPD’.
We can only speculate about the reasons that FVC is low in
poor countries. In some countries different norms are recom-
mended for different ethnic groups16 32 and there is a common
belief that FVC is racially determined, though the evidence for
this is weak.33 In the UK BOLD study, African Caribbean and
Asian, mostly South Asian, participants had similarly reduced
FVC,34 and in the current analysis the associations with poverty
are even stronger when the predominantly white European
populations are excluded. The strongest association is seen in
countries where the GNI is less than US$15 000 per annum and
contains an ethnically very diverse group of communities, includ-
ing populations in India, the Philippines, China, Tunisia and
Turkey, and a Cape coloured community in South Africa which
has a mixed Xhosa, Khoi, European and Malay ancestry. It is
unlikely that genetics could explain away the strong association
between spirometric restriction and poverty in this population.
The observed coincidence of the high prevalence of spirometric
restriction and the high mortality rate from ‘COPD’ is consistent
with the earlier ﬁnding that the prognostic signiﬁcance of a given
FVC is independent of ethnicity and supports our decision not to
adjust the lower limits of normal for ethnicity.35
The high prevalence of spirometric restriction in low-income
countries is likely to be largely due to unknown environmental
causes. There is a strong association with poverty but it is
important to understand how this is mediated. Low birth weight
is associated with spirometric restriction in many studies,26 36–39
and low birth weight is more common in developing countries
(16%) and in the least developed countries (17%) when com-
pared with industrialised countries (7%).40 Speciﬁc exposures
also associated with spirometric restriction include exposure to
indoor air pollution41 and a poor diet.42 More speculative risk
factors include early infections43 and early exposure to biomass
fuel.44
The mechanism by which spirometric restriction leads to
death is also unclear, but it is unlikely that the spirometric
restriction represents a high prevalence of classical restrictive
lung diseases as these conditions are rare. Low ventilatory func-
tion is associated with other comorbidities and the excess deaths
among those with low ventilatory function are often ascribed to
cardiovascular causes.7 Comorbidities could explain some of the
association between low lung volumes, measured as spirometric
restriction or FEV1, and increased mortality.
7 Nevertheless the
fact that the deaths are ascribed to ‘COPD’ suggests that they
are associated with substantial respiratory symptoms.
Tobacco is the highest ranked risk factor for disease burden in
high-income North America and Western Europe and second
only to high blood pressure globally according to the most
recent estimates.45 Nevertheless, in low-income countries other
factors associated with poverty dominate the risk of mortality
attributed to ‘COPD’, even though spirometrically measured
chronic airﬂow obstruction remains overwhelmingly a condition
associated with smoking in all regions. There is a serious danger
that an epidemic of smoking, if ever it were to become estab-
lished in these vulnerable regions, would have even more devas-
tating effects than we have seen so far in the more afﬂuent
countries.
It is unlikely that the high mortality attributed to ‘COPD’,
particularly in low-income countries, is associated with chronic
airﬂow obstruction. It is much more likely to be associated with
spirometric restriction. These analyses challenge us to rethink
our notions and beliefs about the origins and signiﬁcance of
chronic lung disease and its prominent role as a major cause of
death in low-income countries. This by no means reduces the
importance of tobacco control as the most important approach
to the prevention of chronic airﬂow obstruction and other
morbidity.
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